Cannabis: Review of behavioral effects in animals.

Miller, Loren L.; Drew, William G.

doi:10.1037/h0036572

Cited by 31 publications

(5 citation statements)

References 99 publications

(123 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…While our results may be considered as supportive of Miller's and Drew's (1974) pro posal that lI 9-mC has an ticholinergic properties, o ur resu lts may have been due to non specific stim ulant properties of physostigmine rather t han direct antagonism. Indeed, ph ysostigmine has been shown to reverse physiological depression indu ced by a variety of agents not considered to have specific anticholinergic effects.…”

Section: Discussionsupporting

confidence: 61%

“…In conclusion, lI 9 -mc ad ministration produces EEG and behavio ral change s similar to the anticholinergics, atropine and scopo lamin e (Miller & Drew, 1974). Further, these changes can be reversed by phys ostigmine.…”

Section: Discussionmentioning

confidence: 72%

“…Several investigators have suggested that the behavioral effects of~9 -tetrahydrocannabinol (~9 -THC), the major psychoactive component of marihuana, may be one manifestation of its activity at central cholinergic pathways, especially in the limbic system . More specifically, Miller and Drew (1974) believe that~9 -THC has anticholinergic (atropine-like) activity and that this anticholinergic activity is apparent especially in the hippocampus.…”

mentioning

confidence: 99%

See 2 more Smart Citations

Physostigmine-induced reversal of EEG and behavioral effects of Δ9-tetrahydrocannabinol

Jones

Consroe

Akins

1975

Bull. Psychon. Soc.

View full text Add to dashboard Cite

The effects of A' •THC) in combination with physostigmine (PHYSO) on the electroencephalogram (EEG) and behavior were measured in adult unrestrained rabbits. The increase in mean cortical electrogenesis (voltage output) of the EEG induced by A 9-THC was clearly reversed by PHYSO. Hippocampal theta rhythm disrupted by A 9-THC was restored by PHYSO. Physostigmine also antagonized A9-THC-induced alteration of postural and activity behaviors. Except for very brief periods of retching, no behavioral indications of toxicity were observed.

show abstract

Section: Discussionsupporting

confidence: 61%

Section: Discussionmentioning

confidence: 72%

mentioning

confidence: 99%

See 1 more Smart Citation

Physostigmine-induced reversal of EEG and behavioral effects of Δ9-tetrahydrocannabinol

Jones

Consroe

Akins

1975

Bull. Psychon. Soc.

View full text Add to dashboard Cite

show abstract

“…Discussion of cannabis use with clients must be nuanced and should acknowledge and validate the perceived, anecdotal benefits while balancing the explanation that the data are incomplete. For example, initially, researchers falsely believed that THC was solely responsible for cannabis’ psychoactivity and medicinal benefits [48]. Scientists have only recently begun to identify the therapeutic potential of other cannabinoids (e.g., CBD, cannabichromere [CBC], cannabinol [CBN], tetrahydrocannabivarin [THCV]).…”

Section: Clinical Considerationsmentioning

confidence: 99%

Navigating Blind in the Green Rush: Clinical Considerations and Harm Reduction Practices for Cannabis

Meffert

Morabito

Mosich

et al. 2019

CDRR

View full text Add to dashboard Cite

Background. The United States has recently experienced extensive changes in state policy regarding the use of cannabis for recreational and medicinal purposes. Despite its rapidly increasing accessibility and social acceptance, there is a striking dearth of research on cannabis as a treatment for medical and psychological conditions. Research on cannabis is difficult to conduct as it is classified as a schedule I drug with high potential for abuse and currently no accepted medical use in treatment. As a result, no standard dosing procedures exist and the lack of conclusive scientific evidence has left clinical providers without evidence-based guidelines about if, when, and how to guide clients on using cannabis safely. Objective. To (1) provide critical psychoeducational information about cannabis and cannabis problems to guide client-provider conversations about cannabis use and (2) describe common clinical concerns around cannabis use, highlight special considerations for vulnerable populations, and review harm reduction techniques and practical resources that may help clinicians and their clients navigate safer cannabis use. Conclusion. The removal of regulatory barriers would enable researchers to address key public health questions about the potential therapeutic and adverse effects of cannabis use. Additionally, funds for research, clinician education, and public health education initiatives are necessary to reduce risk around cannabis use in the United States.

show abstract

“…Various aspects of Cannabis have been authoritatively reviewed in recent years, including the botany, chemistry, pharmacology, synthesis of active and inactive cannabinoids, metabolism in man and animals, etc. (Abel 1976;Anderson 1974;Bailey 1974;Bech et al 1974;Bhargava 1978;Bloch et al 1978;Braude and Szara 1976a and b;Carr et al 1970;Clark and del Giudice 1978;Graham 1976;Iversen, Iversen and Snyder 1978;Iversen, Iversen and Snyder 1978;Joyce and Curry 1970;Clark and del Giudice 1978;Graham 1976;Lemberger and Rubin 1975;Lewis 1972;Mechoulam 1970Mechoulam , 1973Mechoulam et al 1976;Mendelson et al 1974;Miller and Drew 1974;Morris and Farnsworth 1973;Neumeyer and Shagoury 1971;Paxton and Crown 1972;Quimby 1974;Razdan 1973;Salemink 1978;Salzman 1979;Saulle 1973;Schonhofea 1973;Schultes 1973;Schultes et al 1974;Small 1976 andSmall and Cronquist 1976;Stueck 1979;and Turner et al 1980). Of special interest is a recent annotated bibliography on marihuana, covering all periodical references appearing in the scientific literature from 1964 through 1974 (W...…”

Section: Monoterpenoid Chromenesmentioning

confidence: 99%

Ethnomedical, Botanical and Phytochemical Aspects of Natural Hallucinogens

Schultes¹,

Farnsworth²

1980

Botanical Museum Leaflets, Harvard University

View full text Add to dashboard Cite

More than 200 species and/ or varieties of higher plants, as well as numerous species of basidiomycetes, are reported in the literature to have been used for their hallucinatory and/ or euphoriant effects. Due to a paucity of research, only a few of these have been confirmed as definitely hallucinogenic in man or animals. This article reviews all of those plants now known to have a scientific basis for producing hallucinogenic effects in man or for which reliable ethnobotanical data are available to indicate that they could be hallucinogenic. Those plants alleged to be hallucinatory, but where substantive proof of this effect may be lacking, are summarily included for completeness arid in the hope of stimulating investigation.The hallucinogens of higher plant origin alone are found in 146 genera in more than 50 families. In virtually every instance in which the active constituents are known, their chemical skeletons are unique to a specific genus or to a very closely related genus.It is interesting to note that of more than 200 species of hallucinogenic plants only two are legally prohibited from use in the United States by Federal law: Cannabis sativa and Tabernanthe Iboga. Two or three others are illegal in a few states.

show abstract

Cannabis: Review of behavioral effects in animals.

Cited by 31 publications

References 99 publications

Physostigmine-induced reversal of EEG and behavioral effects of Δ9-tetrahydrocannabinol

Physostigmine-induced reversal of EEG and behavioral effects of Δ9-tetrahydrocannabinol

Navigating Blind in the Green Rush: Clinical Considerations and Harm Reduction Practices for Cannabis

Ethnomedical, Botanical and Phytochemical Aspects of Natural Hallucinogens

Contact Info

Product

Resources

About